RecruitingPhase 2NCT04755920

SGM-101 in Colorectal Brain Metastases.

A Feasibility Study of SGM-101, a Fluorochrome-labeled Anti-carcinoembryonic Antigen Monoclonal Antibody for the Intraoperative Detection of Colorectal Brain Metastases.

Sponsor

Leiden University Medical Center

Enrollment

10 participants

Start Date

Jan 1, 2024

Study Type

INTERVENTIONAL

Conditions

Colorectal Neoplasms Gastrointestinal Cancer Brain Metastases Brain Neoplasms Brain Diseases Brain Tumor Brain Cancer Rectum Cancer Rectal Neoplasms Gastrointestinal Neoplasms Intestinal Neoplasms Gastrointestinal Disease Intestinal Disease

Summary

This study assesses the feasibility of SGM-101, a fluorochrome-labeled anti-carcinoembryonic antigen monoclonal antibody, for intraoperative near-infrared fluorescence imaging of colorectal brain metastases by injecting SGM-101 intravenously 3 - 5 days prior to surgery.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a special imaging agent called SGM-101, which lights up colorectal cancer cells during surgery, to see if it can help surgeons better detect and remove colorectal cancer that has spread to the brain. **You may be eligible if...** - You are 18 years or older - You have colorectal cancer that has spread to the brain (brain metastases) - You are able to use effective contraception if applicable - You are able to communicate and give informed consent **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have serious health conditions that would make participation unsafe - You cannot give informed consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.